KEGG   DRUG: Lenalidomide
Entry
D04687                      Drug                                   
Name
Lenalidomide (JAN/USAN/INN);
Revlimid (TN)
Product
REVLIMID (Celgene Corporation)
  Generic
LENALIDOMIDE (Alvogen), LENALIDOMIDE (Amneal Pharmaceuticals NY LLC), LENALIDOMIDE (Apotex Corp.), LENALIDOMIDE (Aurobindo Pharma Limited), LENALIDOMIDE (BIOCON PHARMA INC.,), LENALIDOMIDE (Camber Pharmaceuticals), LENALIDOMIDE (Cipla USA), LENALIDOMIDE (Cipla USA), LENALIDOMIDE (Dr. Reddy's Laboratories), LENALIDOMIDE (EXELAN PHARMACEUTICALS), LENALIDOMIDE (EXELAN PHARMACEUTICALS), LENALIDOMIDE (Mylan Pharmaceuticals), LENALIDOMIDE (Sun Pharmaceutical Industries), LENALIDOMIDE (Teva Pharmaceuticals), LENALIDOMIDE (Teva Pharmaceuticals), LENALIDOMIDE (Zydus Lifesciences Limited), LENALIDOMIDE (Zydus Pharmaceuticals USA)
Formula
C13H13N3O3
Exact mass
259.0957
Mol weight
259.26
Structure
Simcomp
Class
Anti-inflammatory
 DG01985  Disease modifying anti-rheumatic drug (DMARD)
  DG01936  TNF inhibitor
Remark
Therapeutic category: 4291
ATC code: L04AX04
Chemical structure group: DG00744
Product (DG00744): D04687<JP/US> D09813<JP>
Efficacy
Antineoplastic, Immunomodulator, TNF-alpha inhibitor
  Disease
Multiple myeloma [DS:H00010]
Myelodysplastic syndromes (chromosome 5q deletion) [DS:H01484]
Mantle cell lymphoma [DS:H01464]
Follicular lymphoma [DS:H01613]
Comment
Thalidomide [DR:D00754] derivative
Target
TNF (TNFA, TNFSF2) [HSA:7124] [KO:K03156]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04064  NF-kappa B signaling pathway
hsa04210  Apoptosis
hsa04640  Hematopoietic cell lineage
hsa04650  Natural killer cell mediated cytotoxicity
hsa04668  TNF signaling pathway
Interaction
Structure map
map07046  Immunosuppressive agents
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AX Other immunosuppressants
     L04AX04 Lenalidomide
      D04687  Lenalidomide (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Immunomodulatory Agents
   Imides
    Lenalidomide
     D04687  Lenalidomide (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D04687  Lenalidomide (JAN/USAN/INN)
Drug groups [BR:br08330]
 Anti-inflammatory
  DG01985  Disease modifying anti-rheumatic drug (DMARD)
   DG01936  TNF inhibitor
    DG00744  Lenalidomide
     D04687  Lenalidomide
Drug classes [BR:br08332]
 Immunological agent
  DG01936  TNF inhibitor
   D04687  Lenalidomide
 Antirheumatic agent
  DG01985  Disease modifying anti-rheumatic drug (DMARD)
   D04687  Lenalidomide
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Tumor necrosis factors
    TNF (TNFA, TNFSF2)
     D04687  Lenalidomide (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D04687
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D04687
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D04687
Pharmacogenomic biomarkers [br08341.html]
 Polymorphisms and mutations affecting drug response
  D04687
Drug groups [BR:br08330]
 Anti-inflammatory
  DG01985  Disease modifying anti-rheumatic drug (DMARD)
   DG01936  TNF inhibitor
    DG00744  Lenalidomide
Other DBs
CAS: 191732-72-6
PubChem: 47206522
ChEBI: 63791
LigandBox: D04687
NIKKAJI: J1.121.689G
LinkDB
KCF data

ATOM        19
            1   C8x C    12.8800  -15.7500
            2   C8x C    12.8800  -17.1500
            3   C8x C    14.0924  -17.8500
            4   C8y C    15.3049  -17.1500
            5   C8y C    15.3049  -15.7500
            6   C8y C    14.0924  -15.0500
            7   C5x C    16.6364  -17.5826
            8   N1y N    17.4593  -16.4500
            9   C1x C    16.6364  -15.3174
            10  C1y C    18.8300  -16.4500
            11  O5x O    17.0675  -18.9094
            12  N1a N    14.0924  -13.6502
            13  C1x C    19.5300  -17.6624
            14  C1x C    20.9300  -17.6624
            15  C5x C    21.6300  -16.4500
            16  N1x N    20.9300  -15.2376
            17  C5x C    19.5300  -15.2376
            18  O5x O    18.8396  -14.0421
            19  O5x O    23.0300  -16.4500
BOND        21
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     4   7 1
            8     7   8 1
            9     8   9 1
            10    5   9 1
            11    8  10 1
            12    7  11 2
            13    6  12 1
            14   10  13 1
            15   13  14 1
            16   14  15 1
            17   15  16 1
            18   16  17 1
            19   10  17 1
            20   17  18 2
            21   15  19 2

» Japanese version   » Back

DBGET integrated database retrieval system